Acute hypoxaemic respiratory failure remains a significant cause of mortality in EICU patients. HFNC can provide the oxygen concentration and flow required by the organism, ensure the relative humidity of oxygen, reduce the resistance of the upper respiratory tract, and reduce the energy consumption of the organism, thus effectively alleviating the hypoxic state of patients with ARF. Additionally, it can reduce the degree of CO2 retention in the body, thereby promoting the alleviation of clinical symptoms[2, 3]. Nevertheless, there are still some patients whose conditions remain uncontrolled following ventilation, or even experience an exacerbation of their conditions, which increases the risk of death[4, 5].
The present study sought to examine the characteristics and independent factors predicting treatment failure in patients with acute hypoxaemic expiratory failure treated with high-flow nasal cannula (HFNC). The results demonstrated that the PSI scores, CURB-65 scores, CPIS scores, CT scores and SOFA scores were significantly elevated in the high-flow oxygen therapy failure group in comparison to the high-flow oxygen therapy success group. Within 12 hours of commencing treatment, the oxygen saturation index (PaO2/FiO2) was significantly lower in the high-flow oxygen therapy failure group than in the success group. The concentration of C-reactive protein (CRP), the number of platelets (PLT), the level of D-dimer, the concentration of interleukin-10 (IL-10), the total number of bacteria (TB) and the concentration of creatinine (CB) were significantly higher in the group that did not respond to high-flow oxygen therapy than in the group that did respond. Conversely, the concentration of albumin was significantly lower in the group that did not respond than in the group that did respond. In the multivariate logistic regression analysis model, the CT score, SOFA score, IL-1β and albumin were identified as independent predictors of failure of high-flow nasal oxygen therapy.
HFNC has been demonstrated to reduce the rate of tracheal intubation in patients with acute hypoxaemic respiratory failure. Our results indicated a failure rate of 34.02% for high-flow oxygenation, a result comparable to that observed in a 2015 multicentre, randomised, open-label trial in which high-flow oxygenation was shown to reduce mortality in the intensive care unit and after 90 days[6]. Two additional studies of novel coronaviruses have demonstrated that HFNC treatment is associated with a reduction in the need for invasive mechanical ventilation compared to COT[7, 8]. The reported failure rates of HFNC treatment in patients with severe COVID-19 infection range from 32–57%[9–13]. This may be related to the favourable physiological effects of HFNC[14, 15]. In addition, low levels of positive end-expiratory pressure (PEEP) are employed to maintain alveolar patency, nasopharyngeal dead space is flushed to enhance ventilatory efficiency, respiratory patterns are improved, and airway heating and humidification are enhanced. Nevertheless, studies have also reported HFNC failure in 68% of patients[16]. This discrepancy may be attributed to differences in the definition of HFNC failure across studies and the varying severity of disease among the included patients.
The PSI, CURB-65, CPIS, CT and SOFA scores were found to be significantly higher in the group of patients who did not respond to high-flow oxygen therapy (HFOT) than in those who did respond. In a French study that included 200 patients with COVID-19, the risk factors for HFOT failure were found to be a SAPS-2 score and a CT scan abnormality greater than 75%. These findings are consistent with those of the present study [16].
The results demonstrated that HFNC improved oxygenation and respiratory rate. Oxygenation and index (PaO2/FiO2) was significantly lower in the high-flow oxygen therapy failure group than in the success group at 1h, 6h, and 12h of initiating treatment, and respiratory rate was significantly higher in the high-flow oxygen therapy failure group than in the success group. The oxygenation and respiratory rate began to improve in the HFNC success group at 12 hours of initiating treatment. It has been demonstrated that at 4–6 hours and 24 hours, the respiratory rate decreased in the HFNC group at 4–6 hours compared to COT. This is consistent with the results of the present study [8, 17, 18]. A number of studies have demonstrated that HFNC oxygen therapy is more effective than conventional oxygen therapy in improving respiratory rate (RR) and PaO2/FiO2 in patients with acute respiratory failure [14, 19, 20]。The administration of high-flow oxygen through the nasal passages by means of HFNC not only ensures a high oxygen concentration, but also plays an important role in humidifying the airway[21]. A notable enhancement in oxygen saturation was observed following the utilisation of HFNC in patients presenting with acute respiratory failure. This finding aligns with our previous observations and further substantiates the beneficial effects of HFNC in patients requiring respiratory support[22, 23]. A low oxygen saturation on admission is an important predictor of high-flow nasal oxygen failure [12]。
The levels of CRP, PLT, D-Dimer, TB, CB and IL-10 were found to be significantly higher in the group that had not responded to high flow oxygen therapy, in comparison to the group that had responded. Conversely, the level of albumin was found to be significantly lower in the group that had not responded to high flow oxygen therapy. This reduction in albumin levels has been observed in acutely ill patients [24] and has been associated with a poor prognosis[25]. A study has demonstrated that serum albumin is associated with an increased risk of mortality in patients with COVID-19 [26]. It has been demonstrated that elevated stress CRP, D-dimer, TB and CB levels are associated with increased vascular permeability and organ dysfunction in patients. Furthermore, serum albumin serves as a marker of severe oxidation and is an acute-phase reactant with antioxidant properties. The metabolism of albumin can result in the excretion of reactive oxidants, which can lead to platelet and coagulation activation. This, in turn, can contribute to elevated D-Dimer levels and an increased risk of thrombotic events in critically ill patients with severe hypoalbuminaemia.
In a multivariate logistic regression analysis model, CT score, SOFA score, IL-1β and albumin were identified as independent predictors of treatment failure with high-flow nasal oxygen. In a large study assessing the role of different cytokines in COVID-19 infection, IL-6 demonstrated significant prognostic value[27]. Evaluation of IL-6 levels at the early stage of disease onset allows stratification of higher-risk patients with more severe disease. This study further affirms the value of IL-1β[28].
It should be noted that this study is subject to several limitations. Firstly, this study was retrospective and conducted in a single centre. Consequently, prospective, multicentre validation studies are required to confirm the findings. Secondly, the study excluded patients with multiple EICU admissions in order to avoid the potential for data duplication and bias. Thirdly, the study excluded children under the age of 14 and elderly patients over the age of 90, as the use of HFNC, which is challenging for patients to cooperate with, may introduce bias into the results. The results of this study require further validation with a larger sample size from multiple centres.